About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Canakinumab, a Monoclonal Antibody Reduces Risk of Cardiovascular Events

by Colleen Fleiss on March 13, 2018 at 12:08 AM
Font : A-A+

Canakinumab, a Monoclonal Antibody Reduces Risk of Cardiovascular Events

Among patients with diabetes or those with chronic kidney disease, anti-inflammatory therapy with drug canakinumab lowers rates of major cardiovascular events, reveals new research conducted by Paul Ridker, MD, director of the Center for Cardiovascular Disease Prevention at BWH, and Brendan Everett, MD, director of the General Cardiology Inpatient Service at BWH. Findings related to patients with or at high risk of diabetes were simultaneously published in the Journal of the American College of Cardiology and a paper on the CKD findings is forthcoming.

Two new analyses of data from more than 10,000 heart attack survivors worldwide were presented by investigators from Brigham and Women's Hospital at the 2018 American College of Cardiology meeting.

Advertisement


"Evidence continues to build that inflammation underlies many diseases and health conditions," said Everett. Our data also suggest that as cardiovascular disease and diabetes take root, the inflammatory pathways underlying them may diverge."

Everett and colleagues found that canakinumab was equally effective at reducing rates of cardiovascular events among patients with and without diabetes enrolled in the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). The drug reduced HbA1C levels - a key indicator of glucose tolerance - in patients with diabetes or pre-diabetes for the first six to nine months of the trial, but this effect was not sustained.
Advertisement

In a new analysis led by Ridker, investigators found that canakinumab reduced major adverse cardiovascular event rates among high-risk atherosclerosis patients with moderate to severe chronic kidney disease, with the largest benefits accrued among those who had the most robust anti-inflammatory response. Canakinumab, an IL-1b inhibitor, represents a new class of therapy for atherosclerotic disease that lowers hsCRP and IL-6 with no effect on lipid levels.

"Moving forward, it will be important to extend these data and test the efficacy of canakinumab in patients with end-stage renal failure undergoing dialysis," said Ridker. "In that setting, hsCRP is a powerful predictor of risk while LDL-C is not, and dialysis is one of the only settings where LDL reduction has not been highly effective."

CANTOS was proposed and designed by investigators in the Center for Cardiovascular Disease Prevention at BWH, in collaboration with Novartis Pharmaceuticals. Ridker received financial support for clinical research from Novartis Pharmaceuticals to conduct the CANTOS. Ridker has served as a consultant to Novartis Pharmaceuticals and is listed as a co-inventor on patents held by BWH that relate to the use of inflammatory biomarkers in cardiovascular disease and diabetes that have been licensed to AstraZeneca and Siemens. Other BWH investigators involved in the new CANTOS analyses include Robert Glynn, PhD, Peter Libby, MD, Aruna Pradhan, MD, MPH, and Jean MacFadyen.

Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Category
What's New on Medindia
Is COVID-19 Vaccination during Pregnancy Safe?
Sensory Processing Disorder (SPD)
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Amyotrophic Lateral Sclerosis (ALS) Acute Coronary Syndrome 

Recommended Reading
Heart Attack- Lifestyle risks
Heart attack is the death of the heart muscle due to loss of blood supply. Simple guidelines to ......
Test Your Knowledge on Inflammation
We are uncomfortable when there is a skin injury or an insect bite and we notice the area becomes .....
Canakinumab
This medication is an interleukin-1 beta-blocker, prescribed for auto-inflammatory diseases known .....
More Use of Statins is Recommended to Prevent Cardiovascular Events
Guidelines from the U.S., Canada, Britain are much better in preventing primary atherosclerotic ......
Acute Coronary Syndrome
Acute coronary syndrome (ACS) is a sudden, acute life-threatening condition caused by a dramatic red...
Amyotrophic Lateral Sclerosis (ALS)
Find out more about the degenerative disease- Amyotrophic lateral sclerosis....

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use